Advertisement

Research ArticleOncology Free access | 10.1172/JCI32007

Survival prediction of stage I lung adenocarcinomas by expression of 10 genes

Fabrizio Bianchi,1 Paolo Nuciforo,1 Manuela Vecchi,1 Loris Bernard,1 Laura Tizzoni,1 Antonio Marchetti,2 Fiamma Buttitta,2 Lara Felicioni,2 Francesco Nicassio,1 and Pier Paolo Di Fiore1,3,4

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Bianchi, F. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Nuciforo, P. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Vecchi, M. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Bernard, L. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Tizzoni, L. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Marchetti, A. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Buttitta, F. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Felicioni, L. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Nicassio, F. in: JCI | PubMed | Google Scholar

1IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy. 2Center of Excellence on Aging, University Foundation, Chieti, Italy. 3Istituto Europeo di Oncologia, Milan, Italy. 4Dipartimento di Medicina, Chirurgia ed Odontoiatria, Università degli Studi di Milano, Milan, Italy.

Address correspondence to: Pier Paolo Di Fiore, IFOM, Istituto FIRC di Oncologia Molecolare, Via Adamello 16, 20139 Milan, Italy. Phone: 39-02-574303247; Fax: 39-02-574303231; E-mail: pierpaolo.difiore@ifom-ieo-campus.it.

Find articles by Di Fiore, P. in: JCI | PubMed | Google Scholar

Published October 18, 2007 - More info

J Clin Invest. https://doi.org/10.1172/JCI32007.
© 2007 The American Society for Clinical Investigation
Published October 18, 2007 - Version history
Received: March 2, 2007; Accepted: August 1, 2007
View PDF
Abstract

Adenocarcinoma is the predominant histological subtype of lung cancer, the leading cause of cancer deaths in the world. At stage I, the tumor is cured by surgery alone in about 60% of cases. Markers are needed to stratify patients by prognostic outcomes and may help in devising more effective therapies for poor prognosis patients. To achieve this goal, we used an integrated strategy combining meta-analysis of published lung cancer microarray data with expression profiling from an experimental model. The resulting 80-gene model was tested on an independent cohort of patients using RT-PCR, resulting in a 10-gene predictive model that exhibited a prognostic accuracy of approximately 75% in stage I lung adenocarcinoma when tested on 2 additional independent cohorts. Thus, we have identified a predictive signature of limited size that can be analyzed by RT-PCR, a technology that is easy to implement in clinical laboratories.

Version history
  • Version 1 (October 18, 2007): No description
  • Version 2 (November 1, 2007): No description
Advertisement
Advertisement